Mylan Laboratories (MYL) Receives Final FDA Approval for Glipizide and Metformin Hydrochloride Tablets
More News related to BMY
- Notable ETF Movers: PGM, XLV, SMH Up; UNG, KRE, FXI, AGQ, XME Down
- Bristol-Myers Squibb to Present at Credit Suisse Healthcare Conference
- Bristol-Myers Squibb (BMY) and Alder Biopharma Agree to Develop Rheumatoid Arthritis Treatment
- Bristol-Myers Squibb and Alder Biopharmaceuticals Enter Global Agreement on Rheumatoid Arthritis Biologic
- Emerging Stock Report Initiates Independent Research Coverage On Human Genome Sciences
More News related to MYL
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
- Mylan Receives FDA Approval for Generic Version of Prevacid(R) Through its Subsidiary Matrix Laboratories
- Mylan Labs (MYL) Tops Q3 EPS by 5c, Guides Higher
- Mylan Reports Third Quarter Adjusted Diluted EPS of $0.32
- Trading Radar for 10/29: Exxon (XOM), Motorola (MOT), Waste Management (WM) Report
More News related to FDA
- Kensey Nash (KNSY) Receives FDA Clearance for its First Extracellular Matrix Product, Medeor
- Teva Pharma (TEVA) Gets Final U.S. FDA Approval for Generic Prevacid
- Mylan (MYL) Gets FDA Ok for Generic Prevacid
Mylan Laboratories Inc. (NYSE: MYL) announced that Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Glipizide and Metformin Hydrochloride Tablets in 2.5 mg/ 250 mg, 2.5 mg/500 mg and 5 mg/500 mg strengths.
Glipizide and Metformin Hydrochloride Tablets are the generic version of Bristol Myers Squibb's (NYSE: BMY) Metaglip Tablets.
Related Categories
FDAStocks Mentioned
-0.09Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
